Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 6/20 | 0.47 |
| ▸ | MAOB | P27338 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2213441 | 0.91 | PDE3B (0.47) | UTS2RMEN1KMT2ASLC6A5SIGMAR1 | |
| Trifluoroacetic Acid SCHEMBL2210369 | 0.89 | UTS2R (0.47) | UTS2RMAOBMEN1KMT2AMCHR1 | |
| SCHEMBL2213444 | 0.87 | UTS2R (0.41) | UTS2RMEN1KMT2ANPSR1 | |
| SCHEMBL12511830 | 0.87 | PDE3B (0.51) | UTS2RMEN1KMT2ASIGMAR1MCHR1 | |
| Trifluoroacetic Acid SCHEMBL2208294 | 0.83 | UTS2R (0.44) | UTS2RMAOBMEN1KMT2ASIGMAR1 | |
| Trifluoroacetic Acid SCHEMBL2212565 | 0.83 | UTS2R (0.44) | UTS2RMAOBMEN1KMT2ABCHE | |
| SCHEMBL2211769 | 0.83 | UTS2R (0.44) | UTS2RMAOBMEN1KMT2ASIGMAR1 | |
| Trifluoroacetic Acid SCHEMBL2213098 | 0.83 | UTS2R (0.44) | UTS2RMAOBMEN1KMT2ASIGMAR1 | |
| Trifluoroacetic Acid SCHEMBL6108505 | 0.83 | UTS2R (0.44) | UTS2RMAOBMEN1KMT2ASIGMAR1 | |
| Trifluoroacetic Acid SCHEMBL2214532 | 0.82 | AR (0.46) | UTS2RMAOBMEN1KMT2ABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1389616-B1 | 3,4-Dihalobenzylpiperidine derivatives and their medical use | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-7115635-B2 | Benzylpiperidine compound | MITSUBISHI PHARMA CORPORATION (JP) | 2006-10-03 | — | — | US | disclosed |
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | MITSUBISHI PHARMA CORPORATION (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1389616-A1 | NOVEL BENZYLPIPERIDINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | CCL2, CXCR1, CCR5 | UTS2R 2154/4885MAOB 2634/4885MEN1 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.